Forest Laboratories LLC, et al. v. Sigmapharm Laboratories LLC, et al., C.A. No. 14-1119 – SLR-SRF, January 29, 2016.
Robinson, J. Claim construction opinion issues regarding six terms from three patents.
The disputed technology relates to psychiatry pharmaceuticals. The following terms were considered:
-
“Tension, excitation, anxiety, and psychotic and schizophrenicdisorders:”
-
“Administering sublingually or buccally:”
-
“solid pharmaceutical composition which rapidly disintegrates:”
-
“Orthorhombic"/"Orthorhombiccrystallineform"/"0rthorhombiccrystal form:”
-
“Isolated in a form which contains at least about 90 wt. % of the orthorhombic crystalline form:”
-
“The compound trans-5-chloro-2,3,3a, 12btetrahydro-2-methyl-1 Hdibenz[2,3:6,7]oxepino[4,5-c]pyrrole(Z)-2-butenedioate" and "microcrystalline:"
